Site-specific steric control of SARS-CoV-2 spike glycosylation (Q110137153)

1

0 references

Himanshi Chawla

2

0 references

Firdaus Samsudin

3

0 references

Lorena Zuzic

4

0 references

Aishwary Tukaram Shivgan

5

0 references

Yasunori Watanabe

6

0 references

Wan-Ting He

7

0 references

Sean Callaghan

8

0 references

Ge Song

9

0 references

Peter Yong

10

0 references

Philip J M Brouwer

11

0 references

Yutong Song

12

0 references

Yongfei Cai

13

0 references

Helen M E Duyvesteyn

14

0 references

Tomas Malinauskas

15

0 references

Joeri Kint

16

0 references

Paco Pino

17

0 references

Maria J Wurm

18

0 references

Martin Frank

19

0 references

Bing Chen

20

0 references

David I Stuart

21

0 references

Rogier W Sanders

22

0 references

Raiees Andrabi

23

0 references

Dennis R Burton

24

0 references

Sai Li

25

0 references

Peter J Bond

26

0 references

Max Crispin

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

27

0 references

language of work or name

Englisch

0 references

publication date

9 March 2021

0 references

cites work

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Production of Trimeric SARS-CoV-2 Spike Protein by CHO Cells for Serological COVID-19 Testing

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Membrane lipids: where they are and how they behave

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Stereochemistry of polypeptide chain configurations

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Pre-fusion structure of a human coronavirus spike protein.

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

A composite score for predicting errors in protein structure models

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Optimisation of the cellular metabolism of glycosylation for recombinant proteins produced by Mammalian cell systems

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1.

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

VMD: visual molecular dynamics

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Comparative protein modelling by satisfaction of spatial restraints

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Structural basis for membrane anchoring of HIV-1 envelope spike

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Glycosylation-directed quality control of protein folding

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

N-glycosylation efficiency is determined by the distance to the C-terminus and the amino acid preceding an Asn-Ser-Thr sequon

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Impact of host cell line choice on glycan profile

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Structural principles controlling HIV envelope glycosylation

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Lipids of the Golgi membrane

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Global Aspects of Viral Glycosylation Enveloped viruses/herpesvirus/mass spectrometry/mucin type O-glycosylation/viral glycans.

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Solution structure of the severe acute respiratory syndrome-coronavirus heptad repeat 2 domain in the prefusion state

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

N-glycans of complex glycosylated biopharmaceuticals and their impact on protein clearance

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Polymorphic transitions in single crystals: A new molecular dynamics method

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Sensitive Detection of SARS-CoV-2-Specific Antibodies in Dried Blood Spot Samples

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and retention of the Spike protein, allowing assembly of virus-like particles

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Glycomics and glycoproteomics of viruses: Mass spectrometry applications and insights toward structure-function relationships

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum and saliva enhances detection of infection

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Rapid development of an inactivated vaccine candidate for SARS-CoV-2

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Vulnerabilities in coronavirus glycan shields despite extensive glycosylation

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

An mRNA Vaccine against SARS-CoV-2 - Preliminary Report

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Site-specific glycan analysis of the SARS-CoV-2 spike

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

The inner junction complex of the cilia is an interaction hub that involves tubulin post-translational modifications

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Distinct conformational states of SARS-CoV-2 spike protein

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Distinct conformational states of SARS-CoV-2 spike protein

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

A smooth particle mesh Ewald method

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Site-specific characterisation of SARS-CoV-2 spike glycoprotein receptor binding domain

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

CHARMM-GUI Membrane Builder for Complex Biological Membrane Simulations with Glycolipids and Lipoglycans

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Molecular Architecture of the SARS-CoV-2 Virus

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

CHARMM-GUI Glycan Modeler for modeling and simulation of carbohydrates and glycoconjugates

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Subtle influence of ACE2 glycan processing on SARS-CoV-2 recognition

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Comprehensive Analysis of the Glycan Complement of SARS-CoV-2 Spike Proteins Using Signature Ions-Triggered Electron-Transfer/Higher-Energy Collisional Dissociation (EThcD) Mass Spectrometry

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

The choice of mammalian cell host and possibilities for glycosylation engineering.

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Canonical dynamics: Equilibrium phase-space distributions

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Palmitoylation of the cysteine-rich endodomain of the SARS-coronavirus spike glycoprotein is important for spike-mediated cell fusion.

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Substrate recognition and catalysis by GH47 α-mannosidases involved in Asn-linked glycan maturation in the mammalian secretory pathway

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

A time- and cost-efficient system for high-level protein production in mammalian cells

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

X-ray crystal structures of rabbit N-acetylglucosaminyltransferase I (GnT I) in complex with donor substrate analogues

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Structure of the Lassa virus glycan shield provides a model for immunological resistance

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Molecular dynamics simulation in the grand canonical ensemble.

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

N-glycome signatures in human plasma: associations with physiology and major diseases

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Exploitation of glycosylation in enveloped virus pathobiology

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Structural and functional characterization of SARS-CoV-2 RBD domains produced in mammalian cells

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Ion exchange HPLC microanalysis of chondroitin sulfate: quantitative derivatization of chondroitin lyase digestion products with 2-aminopyridine

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764

Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike

30 December 2021

1 reference

https://api.crossref.org/works/10.1101/2021.03.08.433764